Avinash Aravantagi, MD
Gastroenterology · Bowling Green, KYNPI 1154577336
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,250 of the $44,861 with a category attached, or 71.9%. Phathom Pharmaceuticals, Inc. accounts for 89.7% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $25,884, more than ten times the $556 reported in 2019. Among gastroenterology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $121.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$40K
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$292
- Ironwood Pharmaceuticals, Inc$214
- Pfizer$185
- Johnson & Johnson$170
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$32,25072%
- Travel & lodging$7,31416%
- Food & beverage$5,29012%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 47 | $40,224 |
| AbbVie(2 entities) | 206 | $2,728 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $292 |
| Ironwood Pharmaceuticals, Inc | 14 | $214 |
| Pfizer | 12 | $185 |
| Johnson & Johnson | 10 | $170 |
| Gilead | 8 | $159 |
| Regeneron Healthcare Solutions, Inc. | 6 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $63 |
| Sanofi | 3 | $62 |
| QOL Medical, LLC | 4 | $60 |
| UCB, Inc. | 4 | $59 |
| Daiichi Sankyo Inc. | 3 | $48 |
| Lilly USA, LLC | 3 | $47 |
| Merck | 3 | $44 |
| Redhill Biopharma Inc. | 2 | $43 |
| Bristol Myers Squibb | 3 | $40 |
| Medtronic | 2 | $39 |
| Intercept Pharmaceuticals, Inc. | 2 | $38 |
| Ardelyx, Inc. | 2 | $30 |
| Evoke Pharma, Inc. | 1 | $19 |
| Albireo Pharma, Inc. | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $18 |
| Micro-tech Endoscopy USA, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Celltrion USA Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Amgen | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$39,699
How this compares
$44,861 in reported general payments places this provider in the 95th percentile of 207 gastroenterology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 13 | $86,114 |
| XifaxanRifaximin | 21 | $66,441 |
| LinzessLinaclotide | 39 | $31,525 |
| Mesalamine | 42 | $15,764 |
| VoqueznaVonoprazan Fumarate | 11 | $7,038 |
| MotegrityPrucalopride Succinate | 12 | $6,304 |
| Balsalazide Disodium | 12 | $2,456 |
| Ondansetron Hcl | 12 | $1,951 |
| Sucralfate | 82 | $1,871 |
| Lactulose | 57 | $1,823 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 97 | $1,738 |
| Dexlansoprazole DrDexlansoprazole | 11 | $1,619 |
| Budesonide DrBudesonide | 11 | $1,488 |
| Pantoprazole Sodium | 166 | $1,344 |
| Azathioprine | 20 | $1,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $2,728 | $117,63952 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $292 | $66,44121 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $40,224 | $7,03811 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $63 | $6,30412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 207 gastroenterology providers in Kentucky.
Other gastroenterology in Bowling Green
- Cory FieldingBowling Green$14K
- Ann MonardoBowling Green$8K
- Gerald DrydenLouisville$2.1M
- Zahid SaeedCrestview Hills$442K
- Matthew CaveLouisville$340K
- Michael KreaseLouisville$322K
- Sunana SohiLouisville$220K
- Jeffrey TuvlinLouisville$202K
- Stephen McClaveLouisville$124K
- Uday ShankarHazard$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.